{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:07:50Z","timestamp":1790478470903,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000043","name":"American Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014736","name":"Society for Academic Continuing Medical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014736","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Oncolytics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.omto.2021.05.001","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:26:50Z","timestamp":1620944810000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-0623","authenticated-orcid":false,"given":"Nuttavut","family":"Sumransub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7882-4294","authenticated-orcid":false,"given":"Kornpong","family":"Vantanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-040X","authenticated-orcid":false,"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1386","authenticated-orcid":false,"given":"Emil","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omto.2021.05.001_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.omto.2021.05.001_bib2","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1053\/j.gastro.2010.01.056","article-title":"Colorectal cancer: national and international perspective on the burden of disease and public health impact","volume":"138","author":"Gellad","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omto.2021.05.001_bib3","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omto.2021.05.001_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cam4.2673","article-title":"Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.omto.2021.05.001_bib5","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T\u00a0cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omto.2021.05.001_bib7","doi-asserted-by":"crossref","first-page":"102030","DOI":"10.1016\/j.ctrv.2020.102030","article-title":"Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives","volume":"88","author":"Abdul-Latif","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.omto.2021.05.001_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3390\/cells9030618","article-title":"Immunotherapy, Inflammation and Colorectal Cancer","volume":"9","author":"Lichtenstern","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.omto.2021.05.001_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/fon-2019-0783","article-title":"Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications","volume":"16","author":"Guven","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10620-020-06111-x","article-title":"Gut Microbiome Modulates Response to Cancer Immunotherapy","volume":"65","author":"Khan","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.omto.2021.05.001_bib11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.1999.17.5.1356","article-title":"Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators","volume":"17","year":"1999","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib12","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.2004.09.059","article-title":"Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?","volume":"22","author":"Gill","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"1","key":"10.1016\/j.omto.2021.05.001_bib13","first-page":"CD007046","article-title":"Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer","author":"Des Guetz","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omto.2021.05.001_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/codi.13306","article-title":"Timing of adjuvant chemotherapy in colorectal cancer","volume":"18","author":"Dos Santos","year":"2016","journal-title":"Colorectal Dis."},{"key":"10.1016\/j.omto.2021.05.001_bib15","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0959-8049(99)00150-1","article-title":"CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR","volume":"35","author":"Andr\u00e9","year":"1999","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdw206","article-title":"Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)","volume":"27","author":"Yamazaki","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib18","first-page":"CD008593","article-title":"Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and\/or metastatic colorectal cancer","volume":"2","author":"Wulaningsih","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.omto.2021.05.001_bib19","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib20","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group","volume":"25","author":"Porschen","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib21","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12029-013-9574-7","article-title":"Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer","volume":"45","author":"Loree","year":"2014","journal-title":"J.\u00a0Gastrointest. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis","volume":"34","author":"Guo","year":"2016","journal-title":"Cancer Invest."},{"key":"10.1016\/j.omto.2021.05.001_bib24","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1200\/JCO.1996.14.8.2274","article-title":"Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1","volume":"14","author":"J\u00e4ger","year":"1996","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib25","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1093\/annonc\/mdr031","article-title":"Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients","volume":"22","author":"Cassidy","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib26","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/sj.bjc.6603011","volume":"94","author":"Souglakos","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib27","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","volume":"25","author":"Falcone","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib28","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib29","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00384-009-0655-9","article-title":"A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer","volume":"24","author":"Cao","year":"2009","journal-title":"Int. J. Colorectal Dis."},{"key":"10.1016\/j.omto.2021.05.001_bib32","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdp533","article-title":"Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review","volume":"21","author":"Welch","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib33","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.omto.2021.05.001_bib34","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.3748\/wjg.v21.i16.5072","article-title":"Value of bevacizumab in treatment of colorectal cancer: A meta-analysis","volume":"21","author":"Qu","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2021.05.001_bib35","first-page":"1434","article-title":"Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib36","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/0284186X.2014.961649","article-title":"Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study","volume":"54","author":"Stein","year":"2015","journal-title":"Acta Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","article-title":"Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial","volume":"26","author":"Passardi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib38","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12032-014-0441-6","article-title":"Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer","volume":"32","author":"Kodaz","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib39","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.3748\/wjg.v21.i23.7281","article-title":"Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study","volume":"21","author":"Antonuzzo","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.omto.2021.05.001_bib40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2015.05.016","article-title":"First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis","volume":"96","author":"Pietrantonio","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.omto.2021.05.001_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib42","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib43","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib44","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/sj.bjc.6603847","article-title":"Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options","volume":"97","author":"Scartozzi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib47","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3389\/fphar.2020.00706","article-title":"The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis","volume":"11","author":"Zhong","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omto.2021.05.001_bib48","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the Immune System: Basic Concepts and Targets for Intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib49","first-page":"187","article-title":"CTLA-4 blockade and the renaissance of cancer immunotherapy","volume":"1836","author":"Mocellin","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omto.2021.05.001_bib50","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: Basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omto.2021.05.001_bib51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib52","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T\u00a0cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pag\u00e8s","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib53","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib54","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.omto.2021.05.001_bib55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib56","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib57","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib58","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.05.001_bib59","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib60","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib61","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient\/Microsatellite Instability-High Metastatic Colorectal Cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib62","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High\/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib64","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib65","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2020.04.046","article-title":"Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?","volume":"135","author":"Mans","year":"2020","journal-title":"Eur. J. Cancer"},{"issue":"10 Pt B","key":"10.1016\/j.omto.2021.05.001_bib67","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ejso.2020.06.034","article-title":"Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series","volume":"46","author":"Zhang","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib68","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","article-title":"Advances in Therapeutic Cancer Vaccines","volume":"130","author":"Wong","year":"2016","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.omto.2021.05.001_bib70","doi-asserted-by":"crossref","first-page":"106944","DOI":"10.1016\/j.intimp.2020.106944","article-title":"Therapeutic vaccines for colorectal cancer: The progress and future prospect","volume":"88","author":"Shahnazari","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omto.2021.05.001_bib71","doi-asserted-by":"crossref","first-page":"1796002","DOI":"10.1080\/2162402X.2020.1796002","article-title":"Trial Watch: experimental TLR7\/TLR8 agonists for oncological indications","volume":"9","author":"Frega","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omto.2021.05.001_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jso.20066","article-title":"Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis","volume":"87","author":"Gardini","year":"2004","journal-title":"J.\u00a0Surg. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib74","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.7150\/thno.29035","article-title":"Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?","volume":"8","author":"Fan","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.omto.2021.05.001_bib75","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1007\/s13277-015-3957-2","article-title":"Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study","volume":"37","author":"Lin","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.omto.2021.05.001_bib76","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fphar.2017.00126","article-title":"Dual Functional Capability of Dendritic Cells - Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy","volume":"8","author":"Mosi\u0144ska","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omto.2021.05.001_bib77","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omto.2021.05.001_bib78","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"issue":"Suppl 1","key":"10.1016\/j.omto.2021.05.001_bib79","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2019-129998","article-title":"Next Generation NKG2D-based CAR T-cells (CYAD-02): Co-expression of a Single shRNA Targeting MICA and MICB Improves Cell Persistence and Anti-Tumor Efficacy in\u00a0vivo","volume":"134","author":"Fontaine","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omto.2021.05.001_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12935-021-01763-9","article-title":"Monoclonal antibodies and chimeric antigen receptor (CAR) T\u00a0cells in the treatment of colorectal cancer","volume":"21","author":"Jin","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omto.2021.05.001_bib81","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.05.001_bib82","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.bjc.6605364","article-title":"Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA\/CD3-bispecific T-cell-engaging BiTE antibody","volume":"102","author":"Osada","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib83","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omto.2021.05.001_bib84","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic Viruses in Cancer Treatment: A Review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib85","doi-asserted-by":"crossref","DOI":"10.1007\/s40291-021-00517-7","article-title":"Immuno-Oncolytic Viruses: Emerging Options in the Treatment of Colorectal Cancer","author":"Kana","year":"2021","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.omto.2021.05.001_bib86","first-page":"231","article-title":"A Randomized Phase II Study of FOLFOX6\/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial","volume":"17","author":"Jonker","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.omto.2021.05.001_bib87","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omto.2021.05.001_bib88","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","article-title":"Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy","volume":"21","author":"Rojas","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.05.001_bib89","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"Fabrizio","year":"2018","journal-title":"J.\u00a0Gastrointest. Oncol."},{"issue":"Suppl","key":"10.1016\/j.omto.2021.05.001_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.2019.37.4_suppl.481","article-title":"CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC)","volume":"37","author":"Chen","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib91","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","article-title":"Systematic review of microsatellite instability and colorectal cancer prognosis","volume":"23","author":"Popat","year":"2005","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib92","doi-asserted-by":"crossref","first-page":"264","DOI":"10.14740\/gr1062w","article-title":"Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature","volume":"11","author":"Baran","year":"2018","journal-title":"Gastroenterol. Res."},{"key":"10.1016\/j.omto.2021.05.001_bib93","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","article-title":"Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade","volume":"29","author":"Tang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omto.2021.05.001_bib94","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3389\/fimmu.2019.01816","article-title":"Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?","volume":"10","author":"Ghiringhelli","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omto.2021.05.001_bib95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omto.2021.05.001_bib96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.omto.2021.05.001_bib97","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2021.05.001_bib98","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/2326-6066.CIR-14-0244","article-title":"Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma","volume":"3","author":"Liu","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2021.05.001_bib99","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"Suppl","key":"10.1016\/j.omto.2021.05.001_bib100","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1200\/JCO.2016.34.15_suppl.3539","article-title":"Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients","volume":"34","author":"Segal","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.omto.2021.05.001_bib101","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1200\/JCO.2019.37.15_suppl.3514","article-title":"A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC)","volume":"37","author":"Parikh","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib102","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/2326-6066.CIR-15-0184","article-title":"Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy","volume":"4","author":"Trotta","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"Suppl","key":"10.1016\/j.omto.2021.05.001_bib103","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1200\/JCO.2018.36.4_suppl.834","article-title":"A phase Ib\/II study of cetuximab and pembrolizumab in RAS-wt mCRC","volume":"36","author":"Boland","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.omto.2021.05.001_bib104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2020.38.4_suppl.96","article-title":"Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Final results of the phase II AVETUX trial (AIO-KRK-0216)","volume":"38","author":"Stein","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib105","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/1535-7163.MCT-12-1162","article-title":"Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model","volume":"12","author":"Abou-Elkacem","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omto.2021.05.001_bib106","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib107","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","article-title":"Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial","volume":"27","author":"Cousin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.05.001_bib108","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omto.2021.05.001_bib109","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.omto.2021.05.001_bib110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.omto.2021.05.001_bib112","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/cancers12082317","article-title":"Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge","volume":"12","author":"Marmorino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2021.05.001_bib113","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/jnci\/djt300","article-title":"Human gut microbiome and risk for colorectal cancer","volume":"105","author":"Ahn","year":"2013","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omto.2021.05.001_bib114","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmicb.2015.00020","article-title":"Microbiota disbiosis is associated with colorectal cancer","volume":"6","author":"Gao","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.omto.2021.05.001_bib115","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1126\/science.aaw2367","article-title":"The gut microbiota and colon cancer","volume":"364","author":"Garrett","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib116","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000443358","article-title":"Gastrointestinal Microbiota and Colon Cancer","volume":"34","author":"Hold","year":"2016","journal-title":"Dig. Dis."},{"key":"10.1016\/j.omto.2021.05.001_bib117","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nature18848","article-title":"The microbiota in adaptive immune homeostasis and disease","volume":"535","author":"Honda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omto.2021.05.001_bib118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chom.2013.07.007","article-title":"Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment","volume":"14","author":"Kostic","year":"2013","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.omto.2021.05.001_bib119","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/jamaoncol.2015.1377","article-title":"Fusobacterium nucleatum and T Cells in Colorectal Carcinoma","volume":"1","author":"Mima","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib120","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.tranon.2019.03.003","article-title":"Fusobacterium nucleatum Contributes to the Carcinogenesis of Colorectal Cancer by Inducing Inflammation and Suppressing Host Immunity","volume":"12","author":"Wu","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib121","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1158\/2326-6066.CIR-18-0174","article-title":"Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status","volume":"6","author":"Hamada","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omto.2021.05.001_bib122","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1128\/iai.63.12.4830-4836.1995","article-title":"Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle","volume":"63","author":"Shenker","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.omto.2021.05.001_bib123","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00262-018-2233-x","article-title":"Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism","volume":"67","author":"Chen","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omto.2021.05.001_bib124","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib125","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3390\/cancers12061406","article-title":"The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response","volume":"12","author":"S\u00e1nchez-Alcoholado","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omto.2021.05.001_bib126","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib127","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.canlet.2019.01.015","article-title":"Gut microbiome and cancer immunotherapy","volume":"447","author":"Li","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.omto.2021.05.001_bib128","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib129","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omto.2021.05.001_bib130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib131","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omto.2021.05.001_bib132","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/gutjnl-2016-313498","article-title":"Gut microbiota modulate T\u00a0cell trafficking into human colorectal cancer","volume":"67","author":"Cremonesi","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.omto.2021.05.001_bib133","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T\u00a0cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omto.2021.05.001_bib134","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T\u00a0cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.omto.2021.05.001_bib135","first-page":"81","article-title":"Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials","volume":"16","author":"Park","year":"2020","journal-title":"Curr. Colorectal Cancer Rep."},{"key":"10.1016\/j.omto.2021.05.001_bib136","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"}],"container-title":["Molecular Therapy - Oncolytics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237277052100067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S237277052100067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:21:32Z","timestamp":1762496492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S237277052100067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":136,"alternative-id":["S237277052100067X"],"URL":"https:\/\/doi.org\/10.1016\/j.omto.2021.05.001","relation":{},"ISSN":["2372-7705"],"issn-type":[{"value":"2372-7705","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Oncolytics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omto.2021.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}